Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6% – Here’s What Happened

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price traded up 5.6% on Thursday . The stock traded as high as $47.07 and last traded at $46.2690. 149,968 shares traded hands during trading, a decline of 70% from the average session volume of 492,638 shares. The stock had previously closed at $43.81.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, March 13th. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. UBS Group started coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $59.60.

Oruka Therapeutics Stock Down 2.2%

The business has a 50-day moving average of $35.34 and a 200-day moving average of $29.33. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -23.91 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. Equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 23,765 shares of company stock worth $849,575 in the last 90 days. 24.69% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in Oruka Therapeutics in the second quarter worth $28,000. Ameritas Investment Partners Inc. bought a new position in Oruka Therapeutics during the second quarter valued at about $31,000. BNP Paribas Financial Markets raised its holdings in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $37,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.